Clinical Report: Assessment of Systemic Corticosteroid Use in Atopic Dermatitis

Overview

This study reveals that systemic corticosteroids are still frequently prescribed for atopic dermatitis (AD) in the US, despite clinical guidelines recommending against their routine use. Notably, one in five patients received a prescription, with a significant portion exceeding 90 days, indicating a misalignment with current treatment recommendations.

Background

Atopic dermatitis is a chronic inflammatory skin condition that can severely impact quality of life. While systemic corticosteroids can provide rapid relief, their long-term use is associated with serious adverse effects. With the advent of newer, safer therapies, understanding current corticosteroid prescribing patterns is crucial for improving patient care and aligning practice with clinical guidelines.

Data Highlights

This study utilized US administrative healthcare claims data to analyze systemic corticosteroid prescriptions among patients with atopic dermatitis.

Key Findings

• One in five patients with atopic dermatitis was prescribed systemic corticosteroids.
• Nearly one-quarter of these prescriptions lasted longer than 90 days.
• Current corticosteroid use patterns are inconsistent with clinical guidelines that recommend against routine use.
• There is a pressing need for broader adoption of corticosteroid-sparing treatments.
• Advanced systemic therapies have been approved that offer safer alternatives to corticosteroids.

Clinical Implications

Healthcare providers should be aware of the ongoing use of systemic corticosteroids in atopic dermatitis management and consider alternative therapies that align with current guidelines. Monitoring and educating patients about the risks associated with prolonged corticosteroid use is essential for improving treatment outcomes.

Conclusion

The findings highlight a significant gap between clinical guidelines and real-world prescribing practices for systemic corticosteroids in atopic dermatitis, emphasizing the need for improved treatment strategies.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. AAD Guidelines Update: Phototherapy and Systemic Therapy in Adults With Atopic Dermatitis
6. Full article: Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis
7. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis
8. AAD Guidelines Update on Systemic Therapies
9. Full article: Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3–4 randomized trials
10. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis | British Journal of Dermatology | Oxford Academic